Published in J Clin Invest on January 01, 2007
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol (2011) 8.21
LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev (2008) 3.46
Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol (2011) 2.96
Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res (2008) 1.80
Abnormal patterns of lipoprotein lipase release into the plasma in GPIHBP1-deficient mice. J Biol Chem (2008) 1.73
Molecular processes that handle -- and mishandle -- dietary lipids. J Clin Invest (2008) 1.60
Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene: role of hepatic LDL receptors. J Lipid Res (2008) 1.58
Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest (2009) 1.56
Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J Clin Invest (2007) 1.54
Lipoproteins in Drosophila melanogaster--assembly, function, and influence on tissue lipid composition. PLoS Genet (2012) 1.32
The recovery time course of the endothelial cell glycocalyx in vivo and its implications in vitro. Circ Res (2009) 1.32
Oxygen-mediated enhancement of primary hepatocyte metabolism, functional polarization, gene expression, and drug clearance. Proc Natl Acad Sci U S A (2009) 1.32
Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology (2009) 1.21
Lipids and HCV. Semin Immunopathol (2012) 1.19
Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathog (2010) 1.19
Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses (2010) 1.17
Heparan sulfate proteoglycans are receptors for the cell-surface trafficking and biological activity of transglutaminase-2. J Biol Chem (2009) 1.17
Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance. J Biol Chem (2009) 1.13
The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis (2009) 1.12
Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses (2013) 1.12
The dominating role of N-deacetylase/N-sulfotransferase 1 in forming domain structures in heparan sulfate. J Biol Chem (2011) 1.06
A role for a lithium-inhibited Golgi nucleotidase in skeletal development and sulfation. Proc Natl Acad Sci U S A (2008) 1.04
Altered heparan sulfate structure in mice with deleted NDST3 gene function. J Biol Chem (2008) 0.97
Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. J Clin Invest (2013) 0.95
Syndecan-1 is required to maintain intradermal fat and prevent cold stress. PLoS Genet (2014) 0.94
Deletion of the basement membrane heparan sulfate proteoglycan type XVIII collagen causes hypertriglyceridemia in mice and humans. PLoS One (2010) 0.94
Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins. Hepatology (2010) 0.92
Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size. J Lipid Res (2009) 0.92
Insulin-dependent diabetes mellitus in mice does not alter liver heparan sulfate. J Biol Chem (2010) 0.91
Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice. Arterioscler Thromb Vasc Biol (2013) 0.90
Lowered expression of heparan sulfate/heparin biosynthesis enzyme N-deacetylase/n-sulfotransferase 1 results in increased sulfation of mast cell heparin. J Biol Chem (2011) 0.89
ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest (2016) 0.89
Tetrasulfated disaccharide unit in heparan sulfate: enzymatic formation and tissue distribution. J Biol Chem (2008) 0.89
Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia. Hepatology (2012) 0.86
The glomerular basement membrane as a model system to study the bioactivity of heparan sulfate glycosaminoglycans. Microsc Microanal (2012) 0.86
Complexity of microRNA function and the role of isomiRs in lipid homeostasis. J Lipid Res (2013) 0.86
Retinyl ester hydrolases and their roles in vitamin A homeostasis. Biochim Biophys Acta (2011) 0.85
Low density lipoprotein receptor-related protein 1 dependent endosomal trapping and recycling of apolipoprotein E. PLoS One (2012) 0.85
The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab (2013) 0.85
Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E. PLoS One (2014) 0.85
Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance. Hepatology (2011) 0.85
Human genetic disorders and knockout mice deficient in glycosaminoglycan. Biomed Res Int (2014) 0.85
Role of the N- and C-terminal domains in binding of apolipoprotein E isoforms to heparan sulfate and dermatan sulfate: a surface plasmon resonance study. Biochemistry (2008) 0.83
Glucuronic acid epimerase is associated with plasma triglyceride and high-density lipoprotein cholesterol levels in Turks. Ann Hum Genet (2011) 0.83
Cell type-specific requirements for heparan sulfate biosynthesis at the Drosophila neuromuscular junction: effects on synapse function, membrane trafficking, and mitochondrial localization. J Neurosci (2009) 0.81
Role of heparanase on hepatic uptake of intestinal derived lipoprotein and fatty streak formation in mice. PLoS One (2011) 0.81
Changes in expression of proteoglycan core proteins and heparan sulfate enzymes in the developing and adult murine aorta. J Cardiovasc Transl Res (2011) 0.81
Impaired LDL receptor-related protein 1 translocation correlates with improved dyslipidemia and atherosclerosis in apoE-deficient mice. PLoS One (2012) 0.81
Postprandial triglyceride-rich lipoproteins induce hepatic insulin resistance in HepG2 cells independently of their receptor-mediated cellular uptake. Mol Cell Endocrinol (2011) 0.79
Genetic variation in SULF2 is associated with postprandial clearance of triglyceride-rich remnant particles and triglyceride levels in healthy subjects. PLoS One (2013) 0.79
Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids Health Dis (2016) 0.78
Equivalent binding of wild-type lipoprotein lipase (LPL) and S447X-LPL to GPIHBP1, the endothelial cell LPL transporter. Biochim Biophys Acta (2014) 0.78
The effect of old age on apolipoprotein E and its receptors in rat liver. Age (Dordr) (2009) 0.78
Reducing macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced type I interferon signaling. Cell Metab (2014) 0.78
Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. J Lipid Res (2016) 0.77
microRNA-379 couples glucocorticoid hormones to dysfunctional lipid homeostasis. EMBO J (2014) 0.77
Glycosaminoglycan remodeling during diabetes and the role of dietary factors in their modulation. World J Diabetes (2016) 0.77
SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus. Obesity (Silver Spring) (2014) 0.77
Novel method for reducing plasma cholesterol: a ligand replacement therapy. Clin Lipidol (2015) 0.77
Role of Deacetylase Activity of N-Deacetylase/N-Sulfotransferase 1 in Forming N-Sulfated Domain in Heparan Sulfate. J Biol Chem (2015) 0.77
Apolipoprotein E synthesized by adipocyte and apolipoprotein E carried on lipoproteins modulate adipocyte triglyceride content. Lipids Health Dis (2014) 0.76
Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans. Front Physiol (2015) 0.76
Ext1 heterozygosity causes a modest effect on postprandial lipid clearance in humans. J Lipid Res (2015) 0.76
SMAD about HCV cell entry and pathogenesis of liver disease. Gastroenterology (2016) 0.75
Liver heparan sulfate proteoglycans: old molecules provide new insights on lipoprotein metabolism. Hepatology (2007) 0.75
Serglycin protects against high fat diet-induced increase in serum LDL in mice. Glycoconj J (2015) 0.75
Diet-induced hypercholesterolemia alters liver glycosaminoglycans and associated-lipoprotein receptors in rats. J Physiol Biochem (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
A modified uronic acid carbazole reaction. Anal Biochem (1962) 34.83
Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem (1999) 11.87
Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest (1993) 9.56
Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem (2001) 7.87
An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem (2001) 6.90
DNA excision in liver by an albumin-Cre transgene occurs progressively with age. Genesis (2000) 5.09
Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol (2005) 3.82
Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy. Arteriosclerosis (1981) 3.74
Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest (1998) 3.06
Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci U S A (2002) 2.93
Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature (1999) 2.82
Sustained somatic gene inactivation by viral transfer of Cre recombinase. Nat Biotechnol (1996) 2.71
Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J Clin Invest (1999) 2.66
Mammalian brain morphogenesis and midline axon guidance require heparan sulfate. Science (2003) 2.53
Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J Clin Invest (1995) 2.48
Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor. Proc Natl Acad Sci U S A (1982) 2.43
Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res (1999) 2.39
Heparin is essential for the storage of specific granule proteases in mast cells. Nature (1999) 2.34
Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem (1993) 2.23
Heparan sulfate structure in mice with genetically modified heparan sulfate production. J Biol Chem (2004) 2.14
Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem (1993) 1.92
Hepatic uptake of chylomicron remnants. J Lipid Res (1997) 1.78
Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/N-sulfotransferase-1. J Biol Chem (2000) 1.76
Liver heparan sulfate structure. A novel molecular design. J Biol Chem (1994) 1.76
Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development (2005) 1.69
Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem Sci (2003) 1.67
Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J Biol Chem (1992) 1.60
Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J Clin Invest (1990) 1.58
The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest (1997) 1.55
Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. J Biol Chem (2002) 1.53
Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism. Curr Opin Lipidol (1997) 1.53
Targeted disruption of NDST-1 gene leads to pulmonary hypoplasia and neonatal respiratory distress in mice. FEBS Lett (2000) 1.51
Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol (2004) 1.49
Isolation and characterization of apolipoprotein E. Methods Enzymol (1986) 1.39
Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene. J Biol Chem (1995) 1.35
Enhanced binding and uptake of remnant lipoproteins by hepatic lipase-secreting hepatoma cells in culture. J Biol Chem (1994) 1.27
Apolipoprotein E localization in rat hepatocytes by immunogold labeling of cryothin sections. J Lipid Res (1990) 1.23
Interaction of the N-terminal domain of apolipoprotein E4 with heparin. Biochemistry (2001) 1.21
Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase. J Biol Chem (1994) 1.20
Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. Clin Chem (1986) 1.19
Structural characterization of human liver heparan sulfate. Biochim Biophys Acta (2004) 1.18
New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E. J Biol Chem (2001) 1.17
The unstirred water layer as a site of control of apolipoprotein B secretion. J Biol Chem (1990) 1.14
Heparan sulfate proteoglycans participate in hepatic lipaseand apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J Biol Chem (1997) 1.13
Perlecan heparan sulfate proteoglycan: a novel receptor that mediates a distinct pathway for ligand catabolism. J Biol Chem (2000) 1.13
Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes (1983) 1.13
Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem (1994) 1.12
Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J Biol Chem (1996) 1.12
Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J Lipid Res (1995) 1.12
Nitrocellulose filter binding to assess binding of glycosaminoglycans to proteins. Methods Enzymol (2003) 1.11
The low density lipoprotein receptor-related protein complexes with cell surface heparan sulfate proteoglycans to regulate proteoglycan-mediated lipoprotein catabolism. J Biol Chem (2003) 1.10
Hepatic catabolism of remnant lipoproteins: where the action is. Arterioscler Thromb Vasc Biol (2004) 1.09
Heparin-binding defective lipoprotein lipase is unstable and causes abnormalities in lipid delivery to tissues. J Clin Invest (2001) 1.08
Regulated translation of heparan sulfate N-acetylglucosamine N-deacetylase/n-sulfotransferase isozymes by structured 5'-untranslated regions and internal ribosome entry sites. J Biol Chem (2002) 1.07
Preparation, characterization, and measurement of hepatic lipase. Methods Enzymol (1986) 1.06
Density gradient ultracentrifugation of serum lipoproteins in a swinging bucket rotor. Methods Enzymol (1986) 1.06
Identification and characterization of the endothelial cell surface lipoprotein lipase receptor. J Biol Chem (1991) 1.05
Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Curr Atheroscler Rep (2004) 1.05
Lactoferrin binding to heparan sulfate proteoglycans and the LDL receptor-related protein. Further evidence supporting the importance of direct binding of remnant lipoproteins to HSPG. Arterioscler Thromb (1994) 0.99
Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest (2000) 0.98
Heparin decreases the degradation rate of lipoprotein lipase in adipocytes. J Biol Chem (1987) 0.95
Sensitive high-performance liquid chromatographic method with fluorometric detection for the determination of heparin and heparan sulfate in biological samples: application to human urinary heparan sulfate. J Chromatogr B Biomed Sci Appl (1997) 0.94
Loss of heparan N-sulfotransferase in diabetic liver: role of angiotensin II. Diabetes (2005) 0.94
Glycosylphosphatidylinositol-anchored and core protein-intercalated heparan sulfate proteoglycans in rat ovarian granulosa cells have distinct secretory, endocytotic, and intracellular degradative pathways. J Biol Chem (1992) 0.93
Hepatic lipase is abundant on both hepatocyte and endothelial cell surfaces in the liver. J Lipid Res (1997) 0.92
Apoprotein C-III deficiency markedly stimulates triglyceride secretion in vivo: comparison with apoprotein E. Am J Physiol Endocrinol Metab (2001) 0.90
Binding of hepatic lipase to heparin. Identification of specific heparin-binding residues in two distinct positive charge clusters. J Lipid Res (2000) 0.90
Heparan sulfate proteoglycan-mediated uptake of apolipoprotein E-triglyceride-rich lipoprotein particles: a major pathway at physiological particle concentrations. Biochemistry (1997) 0.89
Changes in matrix proteoglycans induced by insulin and fatty acids in hepatic cells may contribute to dyslipidemia of insulin resistance. Diabetes (2001) 0.89
Cell surface heparan sulfate promotes replication of Toxoplasma gondii. Infect Immun (2005) 0.88
Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J Lipid Res (1998) 0.88
Lipoprotein lipase in liver. Release by heparin and immunocytochemical localization. Biochim Biophys Acta (1988) 0.87
Mapping the heparin-binding domain of human hepatic lipase. Biochem Biophys Res Commun (2006) 0.87
Decreased activity of the heparan sulfate-modifying enzyme glucosaminyl N-deacetylase in hepatocytes from streptozotocin-diabetic rats. J Biol Chem (1991) 0.85
Genetics and molecular biology of hepatic lipase. Curr Opin Lipidol (1996) 0.85
Differences in the mechanisms of uptake and endocytosis of small and large chylomicron remnants by rat liver. Hepatology (1996) 0.85
Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia. J Lipid Res (1995) 0.84
Isolation and characterization of low sulfated heparan sulfate sequences with affinity for lipoprotein lipase. J Biol Chem (2006) 0.83
Enzyme-linked immunosorbent assay for rat hepatic triglyceride lipase. J Lipid Res (1985) 0.81
Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu). J Clin Invest (1995) 0.81
Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature (2007) 7.87
A comprehensive classification system for lipids. J Lipid Res (2005) 6.52
A myocardial lineage derives from Tbx18 epicardial cells. Nature (2008) 6.15
The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer (2005) 5.98
Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab (2007) 5.04
Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med (2003) 4.47
Innate and acquired immunity in atherogenesis. Nat Med (2002) 4.22
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol (2005) 3.82
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65
Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab (2010) 3.29
Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 3.28
Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest (2004) 3.23
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15
Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol (2009) 2.99
Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest (2011) 2.99
Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol (2011) 2.96
Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res (2011) 2.89
Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation (2002) 2.80
GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab (2010) 2.75
Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest (2009) 2.75
Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem (2002) 2.66
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells. Cell Host Microbe (2007) 2.64
IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest (2004) 2.56
Critical role of IL-17RA in immunopathology of influenza infection. J Immunol (2009) 2.51
Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.48
Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol (2005) 2.41
Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest (2003) 2.39
C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A (2002) 2.20
Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med (2004) 2.10
Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med (2014) 2.06
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med (2015) 2.03
GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons. Curr Opin Lipidol (2007) 2.01
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation (2004) 1.97
Oxidative damage in multiple sclerosis lesions. Brain (2011) 1.95
Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation (2008) 1.91
Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest (2002) 1.91
Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J Biol Chem (2005) 1.91
The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons. J Biol Chem (2008) 1.91
Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling. J Biol Chem (2008) 1.91
Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholesterolemic zebrafish. Circ Res (2009) 1.89
Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum (2005) 1.89
Mice deficient in Ext2 lack heparan sulfate and develop exostoses. Development (2005) 1.84
Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat Methods (2008) 1.84
T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A (2005) 1.82
Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol (2007) 1.79
A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res (2008) 1.79
Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation (2006) 1.77
Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol (2009) 1.77
Antioxidant vitamin supplements and cardiovascular disease. Circulation (2004) 1.76
Demystifying heparan sulfate-protein interactions. Annu Rev Biochem (2014) 1.76
Abnormal patterns of lipoprotein lipase release into the plasma in GPIHBP1-deficient mice. J Biol Chem (2008) 1.73
Caenorhabditis elegans early embryogenesis and vulval morphogenesis require chondroitin biosynthesis. Nature (2003) 1.73
Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation (2004) 1.70
Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development (2005) 1.69
Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol (2004) 1.68
Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation (2008) 1.68
Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J Biol Chem (2001) 1.67
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol (2003) 1.66
Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation (2009) 1.65
The role of natural antibodies in atherogenesis. J Lipid Res (2005) 1.65
Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ Res (2009) 1.63
Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol (2002) 1.62
Helix-loop-helix factor inhibitor of differentiation 3 regulates interleukin-5 expression and B-1a B cell proliferation. Arterioscler Thromb Vasc Biol (2013) 1.61
Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res (2006) 1.61
Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc Genet (2010) 1.60
Phosphocholine as a pattern recognition ligand for CD36. J Lipid Res (2005) 1.59
Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol (2004) 1.58
Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol (2010) 1.56
Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HL-dependent hepatic cholesterol uptake. Arterioscler Thromb Vasc Biol (2007) 1.56
Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest (2009) 1.56
Symbol nomenclature for glycan representation. Proteomics (2009) 1.56
Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol (2012) 1.55
Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation (2008) 1.55
Highly conserved cysteines within the Ly6 domain of GPIHBP1 are crucial for the binding of lipoprotein lipase. J Biol Chem (2009) 1.54
Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest (2008) 1.54
Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest (2008) 1.52
Circulating autoantibodies to oxidized LDL correlate with impaired coronary endothelial function after cardiac transplantation. Arterioscler Thromb Vasc Biol (2002) 1.51
The role of innate immunity in atherogenesis. J Lipid Res (2008) 1.50
Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest (2005) 1.49
A focused microarray approach to functional glycomics: transcriptional regulation of the glycome. Glycobiology (2005) 1.49
Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation (2003) 1.49
Heparan sulfate biosynthetic gene Ndst1 is required for FGF signaling in early lens development. Development (2006) 1.46
Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem (2001) 1.44
Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation (2002) 1.43
Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest (2013) 1.43
Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation (2004) 1.43
Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat Chem Biol (2012) 1.43
Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest (2014) 1.42
Resistance to a bacterial toxin is mediated by removal of a conserved glycosylation pathway required for toxin-host interactions. J Biol Chem (2003) 1.41